These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 16250633)

  • 1. A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats.
    Hummel CW; Geiser AG; Bryant HU; Cohen IR; Dally RD; Fong KC; Frank SA; Hinklin R; Jones SA; Lewis G; McCann DJ; Rudmann DG; Shepherd TA; Tian H; Wallace OB; Wang M; Wang Y; Dodge JA
    J Med Chem; 2005 Nov; 48(22):6772-5. PubMed ID: 16250633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A selective estrogen receptor modulator for the treatment of hot flushes.
    Wallace OB; Lauwers KS; Dodge JA; May SA; Calvin JR; Hinklin R; Bryant HU; Shetler PK; Adrian MD; Geiser AG; Sato M; Burris TP
    J Med Chem; 2006 Feb; 49(3):843-6. PubMed ID: 16451049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New scaffolds for the design of selective estrogen receptor modulators.
    Martín-Santamaría S; Rodríguez JJ; de Pascual-Teresa S; Gordon S; Bengtsson M; Garrido-Laguna I; Rubio-Viqueira B; López-Casas PP; Hidalgo M; de Pascual-Teresa B; Ramos A
    Org Biomol Chem; 2008 Oct; 6(19):3486-96. PubMed ID: 19082149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor ligands. Part 6: Synthesis and binding affinity of dihydrobenzodithiins.
    Tan Q; Birzin ET; Chan W; Yang YT; Pai LY; Hayes EC; DaSilva CA; DiNinno F; Rohrer SP; Schaeffer JM; Hammond ML
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3753-5. PubMed ID: 15203156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
    Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Geiser M; Halleux C; Kallen J; Keller H; Ramage P
    J Med Chem; 2005 Jan; 48(2):364-79. PubMed ID: 15658851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor alpha modulators.
    Kim S; Wu JY; Birzin ET; Frisch K; Chan W; Pai LY; Yang YT; Mosley RT; Fitzgerald PM; Sharma N; Dahllund J; Thorsell AG; DiNinno F; Rohrer SP; Schaeffer JM; Hammond ML
    J Med Chem; 2004 Apr; 47(9):2171-5. PubMed ID: 15084115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective estrogen receptor-beta (SERM-beta) compounds modulate raphe nuclei tryptophan hydroxylase-1 (TPH-1) mRNA expression and cause antidepressant-like effects in the forced swim test.
    Clark JA; Alves S; Gundlah C; Rocha B; Birzin ET; Cai SJ; Flick R; Hayes E; Ho K; Warrier S; Pai L; Yudkovitz J; Fleischer R; Colwell L; Li S; Wilkinson H; Schaeffer J; Wilkening R; Mattingly E; Hammond M; Rohrer SP
    Neuropharmacology; 2012 Nov; 63(6):1051-63. PubMed ID: 22796107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen dependent mammary gland virilism in rats given the selective estrogen receptor modulator LY2066948 hydrochloride.
    Rudmann DG; Cohen IR; Robbins MR; Coutant DE; Henck JW
    Toxicol Pathol; 2005; 33(6):711-9. PubMed ID: 16263696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen.
    Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
    J Pharmacol Exp Ther; 2002 Oct; 303(1):196-203. PubMed ID: 12235251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigations on the effects of basic side chains on the hormonal profile of (4R,5S)/(4S,5R)-4,5-bis(4-hydroxyphenyl)-2-imidazolines.
    von Rauch M; Busch S; Gust R
    J Med Chem; 2005 Jan; 48(2):466-74. PubMed ID: 15658860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of potent ligands for estrogen receptor beta by structure-based virtual screening.
    Shen J; Tan C; Zhang Y; Li X; Li W; Huang J; Shen X; Tang Y
    J Med Chem; 2010 Jul; 53(14):5361-5. PubMed ID: 20553023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland.
    Crabtree JS; Peano BJ; Zhang X; Komm BS; Winneker RC; Harris HA
    Mol Cell Endocrinol; 2008 Jun; 287(1-2):40-6. PubMed ID: 18367319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benzothiophene and naphthalene derived constrained SERMs.
    Wallace OB; Bryant HU; Shetler PK; Adrian MD; Geiser AG
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5103-6. PubMed ID: 15380208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
    Grese TA; Pennington LD; Sluka JP; Adrian MD; Cole HW; Fuson TR; Magee DE; Phillips DL; Rowley ER; Shetler PK; Short LL; Venugopalan M; Yang NN; Sato M; Glasebrook AL; Bryant HU
    J Med Chem; 1998 Apr; 41(8):1272-83. PubMed ID: 9548817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation.
    Geiser AG; Hummel CW; Draper MW; Henck JW; Cohen IR; Rudmann DG; Donnelly KB; Adrian MD; Shepherd TA; Wallace OB; McCann DJ; Oldham SW; Bryant HU; Sato M; Dodge JA
    Endocrinology; 2005 Oct; 146(10):4524-35. PubMed ID: 16002528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety.
    Richardson TI; Frank SA; Wang M; Clarke CA; Jones SA; Ying BP; Kohlman DT; Wallace OB; Shepherd TA; Dally RD; Palkowitz AD; Geiser AG; Bryant HU; Henck JW; Cohen IR; Rudmann DG; McCann DJ; Coutant DE; Oldham SW; Hummel CW; Fong KC; Hinklin R; Lewis G; Tian H; Dodge JA
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3544-9. PubMed ID: 17482463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia.
    Norman BH; Dodge JA; Richardson TI; Borromeo PS; Lugar CW; Jones SA; Chen K; Wang Y; Durst GL; Barr RJ; Montrose-Rafizadeh C; Osborne HE; Amos RM; Guo S; Boodhoo A; Krishnan V
    J Med Chem; 2006 Oct; 49(21):6155-7. PubMed ID: 17034120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of the selective estrogen receptor modulators, methyl-piperidino-pyrazole (MPP), and raloxifene in normal and cancerous endometrial cell lines and in the murine uterus.
    Davis AM; Ellersieck MR; Grimm KM; Rosenfeld CS
    Mol Reprod Dev; 2006 Aug; 73(8):1034-44. PubMed ID: 16688783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of two novel selective estrogen receptor modulators, raloxifene, tamoxifen, and ethinyl estradiol on the uterus, vagina and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis).
    Sikoski P; Register TC; Lees CJ; Lundeen S; Hutchison J; Brown KH; Cline JM
    Am J Obstet Gynecol; 2007 Jan; 196(1):75.e1-7. PubMed ID: 17240242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats.
    Wang XN; Simmons HA; Salatto CT; Cosgrove PG; Thompson DD
    Menopause; 2006; 13(4):609-20. PubMed ID: 16837883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.